IR@PKUHSC  > 北京大学临床肿瘤学院  > 胃肠肿瘤中心
学科主题临床医学
High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients
Huang, Hao1; Han, Yong1; Gao, Jing2; Feng, Junnan1; Zhu, Lei3; Qu, Like1; Shen, Lin2; Shou, Chengchao1
关键词Advanced gastric cancer Serum iTRAQ AMBP Chemoresistance
刊名MEDICAL ONCOLOGY
2013-12-01
DOI10.1007/s12032-013-0748-8
30期:4
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]QUANTITATIVE PROTEOMICS ; 1ST-LINE CHEMOTHERAPY ; PROTEIN ; RESISTANCE ; BIOMARKER ; ALPHA(1)-MICROGLOBULIN ; MECHANISMS ; INHIBITOR ; PROGNOSIS ; THERAPY
英文摘要

Gastric cancer is one of the most common human cancers and ranks the second in the global cancer-related mortality. The clinical outcome of patients with advanced gastric cancer (AGC) is markedly dependent on their response to the chemotherapy. Paclitaxel plus capecitabine, as a first-line regimen, is widely administrated in AGC patients, but more than a half of the patients have a poor response, possibly due to their resistance to the treatment. Therefore, it is important to identify potential responders to improve the efficacy of the chemotherapy. In the present study, we used an isobaric tag approach for relative and absolute quantification combined with ESI-QUAD-TOF/MS to identify potential predictive biomarkers for the chemotherapy. We found 211 serum proteins, and confirmed 17 candidates that were differentially present in the progression of disease (PD) group and the partial response (PR) group to the treatment of paclitaxel plus capecitabine. In further validation of the 17 candidates in the set of 12 PD and 12 PR AGC patients, we identified a higher level of AMBP (Alpha-1-Microglobulin/Bikunin Precursor) in the sera of PD patients than of the PR patients assayed by ELISA (9.13 +/- 0.45 vs. 8.11 +/- 0.26 mu g/mL, p = 0.06) and by the Western blotting (relative gray value 396.4 +/- 39.1 vs. 275.0 +/- 34.76, p = 0.03), respectively. The receiver operating characteristics curve showed 75 % sensitivity and 75 % specificity of AMBP in AGC patients treated with the chemotherapy. Our data indicated that the high level of serum AMBP could predict the poor response of the AGC patients treated with the paclitaxel-capecitabine chemotherapy, which could be used as a potential biomarker to identify patients who would benefit from this chemotherapeutic regimen.

语种英语
WOS记录号WOS:000327858800015
项目编号2010CB5529303 ; Z11110706730000
资助机构National Basic Research Program of China ; Beijing Municipal Science and Technology Commission Program
引用统计
被引频次:14[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65100
专题北京大学临床肿瘤学院_胃肠肿瘤中心
北京大学临床肿瘤学院_消化肿瘤内科
北京大学临床肿瘤学院_生化与分子生物学研究室
作者单位1.Peking Univ, Canc Hosp & Inst, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
3.Beijing Prot Innovat Co Ltd, Beijing 101318, Peoples R China
推荐引用方式
GB/T 7714
Huang, Hao,Han, Yong,Gao, Jing,et al. High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients[J]. MEDICAL ONCOLOGY,2013,30(4).
APA Huang, Hao.,Han, Yong.,Gao, Jing.,Feng, Junnan.,Zhu, Lei.,...&Shou, Chengchao.(2013).High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.MEDICAL ONCOLOGY,30(4).
MLA Huang, Hao,et al."High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients".MEDICAL ONCOLOGY 30.4(2013).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Huang, Hao]的文章
[Han, Yong]的文章
[Gao, Jing]的文章
百度学术
百度学术中相似的文章
[Huang, Hao]的文章
[Han, Yong]的文章
[Gao, Jing]的文章
必应学术
必应学术中相似的文章
[Huang, Hao]的文章
[Han, Yong]的文章
[Gao, Jing]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。